Early Detection Cancer Screening

The Beat Cancer Foundation is proud to announce a groundbreaking partnership with Oncosure Testing to bring OncoSure™ Advanced Cancer Screening Technology to patients nationwide. This revolutionary advancement in cancer detection sets a new industry standard, empowering individuals with a rapid, highly accurate blood test capable of detecting all human cancers at the earliest possible stage - even before conventional staging begins.

Traditional cancer screening methods often fall short, limited in scope, invasive, time-consuming, and costly. OncoSure changes everything.

Revolutionary breakthrough in cancer detection that sets a new standard for the industry. A game-changing leap forward for cancer diagnostics. Enter the world where cancer detection isn’t bound by the limitations of traditional diagnostics

OncoSure Testing

Overview

OncoSure™ offers ultra-fast detection of all human cancers using non-invasive liquid biopsy technology. It uses plasma-based peripheral blood samples to enumerate oncosomes — extracellular vesicles derived solely from cancer cells. With a 24-hour turnaround, OncoSure represents a game-changing leap forward in cancer diagnostics.

Why It Matters

Traditional cancer detection relies on invasive and expensive methods such as MRI, CT, and PET scans. OncoSure provides a simple, affordable, and rapid alternative — catching cancer at stage -1, well before symptoms appear.

The Technology

• Sample Source: Plasma-based peripheral blood
• Target Organelle: Oncosomes
• Detection Method: Enumeration and profiling
• Turnaround Time: 24 hours

Clinical Performance

• Sensitivity: 98.44%
• Specificity: 97.15%
• Accuracy: 97.77%
• Current Monitoring Accuracy: 99.9%

Insurance-Friendly

OncoSure accepts most major PPO and Commercial insurance plans, including Medicare and Medicaid. Patients should verify coverage with OncoSure directly.